Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the transaction, the chief financial officer now directly owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Syndax Pharmaceuticals Trading Down 1.0 %

Shares of SNDX traded down $0.15 during mid-day trading on Wednesday, reaching $14.86. The company had a trading volume of 3,212,288 shares, compared to its average volume of 2,342,525. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -4.09 and a beta of 0.90. The firm has a fifty day simple moving average of $14.00 and a 200-day simple moving average of $17.27. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.06 and a fifty-two week high of $25.34.

Analyst Ratings Changes

Several analysts have commented on SNDX shares. The Goldman Sachs Group lifted their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Scotiabank lowered their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.20.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SNDX. Creative Planning lifted its holdings in shares of Syndax Pharmaceuticals by 27.4% during the 2nd quarter. Creative Planning now owns 18,428 shares of the company’s stock valued at $378,000 after acquiring an additional 3,962 shares in the last quarter. Inspire Investing LLC lifted its holdings in shares of Syndax Pharmaceuticals by 23.2% during the 3rd quarter. Inspire Investing LLC now owns 21,308 shares of the company’s stock valued at $410,000 after acquiring an additional 4,018 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Syndax Pharmaceuticals by 8.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 466,028 shares of the company’s stock valued at $8,971,000 after acquiring an additional 37,079 shares in the last quarter. Values First Advisors Inc. acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter valued at $30,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after acquiring an additional 541 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).